Impact of Body Mass Index on Surgical and Oncological Outcomes in Laparoscopic Total Mesorectal Excision for Locally Advanced Rectal Cancer after Neoadjuvant 5-Fluorouracil-Based Chemoradiotherapy
Table 3
Univariate and multivariate analysis of perioperative complications for patients with locally advanced rectal cancer after nCRT.
Variables
Complication (−)
Complication (+)
Univariate
Multivariate
value
OR
95% CI
value
Age (year)
54. 1 ± 11.0
57.5 ± 12.5
0.040
0.268
0.963–1.030
0.136
Gender
0.529
Male
156 (65.3)
48 (65.8)
Female
83 (34.7)
25 (34.2)
BMI (kg/m2)
0.525
<25
191 (79.9)
58 (79.5)
≥25
48 (20.1)
15 (20.5)
ASA score
0.002
1
172 (72.0)
37 (50.7)
1
2
63 (26.4)
32 (43.8)
2.755
1.253–6.060
0.012
3
4 (1.7)
4 (5.5)
6.274
1.123–35.039
0.036
Previous laparotomy history
25 (10.5)
7 (9.6)
0.829
Tumor distance from the anal verge (cm)
6.0 ± 1.9
5.6 ± 2.2
0.129
Tumor diameter (cm)
2.9 ± 1.0
2.9 ± 1.1
0.491
Radiation dose (cGy)
4869.8 ± 443.2
4908.5 ± 336.5
0.426
Interval to surgery (weeks)
8.0 ± 2.0
8.4 ± 2.4
0.229
Surgical type
<0.001
Sphincter-preserving surgery
226 (94.6)
54 (74.0)
1
Abdominoperineal resection
13 (5.4)
19 (26.0)
4.972
2.178–11.349
<0.001
Diverting stoma
135 (56.4)
26 (35.6)
0.002
0.527
0.289–0.963
0.037
Conversion
10 (4.2)
3 (4.1)
0.639
Operative time (min)
209.0 ± 41.1
218.5 ± 49.6
0.143
Estimated blood loss (ml)
64.0 ± 88.3
69.7 ± 60.1
0.606
Pathological TNM stage
0.299
0
40 (16.7)
18 (24.7)
I
61 (25.5)
15 (20.5)
II
72 (30.1)
17 (23.3)
III
66 (27.6)
23 (31.5)
Rectal cancer regression grade
0.967
1
126 (52.7)
39 (53.4)
2
91 (38.1)
28 (38.4)
3
22 (9.2)
6 (8.2)
Data are expressed as number (%) or as median ± standard deviation, where appropriate. OR: odds ratio; CI: confidential interval; BMI: body mass index; ASA: American Society of Anesthesiologists. aIncluding mucinous and signet cell carcinoma.
